Sentynl Therapeutics, a US biopharmaceutical subsidiary of Zydus Lifesciences (formerly Cadila Healthcare), has acquired the global rights of the new drug, fosdenopterin, indicated for reducing the risk of mortality in patients with molybdenum cofactor deficiency (MoCD), The drug, branded as NULIBRY, was developed by BridgeBio Pharma, Inc., which focuses on genetic diseases and cancers.  MoCD is a type A, an ultra-rare, life-threatening paediatric genetic disorder.